onc Videos

Videos

Neal Shore, MD, Carolina Urologic Research Center

Conference Coverage

Impact of Suspended Enzalutamide Monotherapy on Metastasis-Free Survival Among Patients With High-Risk Biochemically Recurrent Prostate Cancer

01/26/2024

Neal Shore , MD, FACS;

Neal Shore, MD, discusses results from the phase 3 EMBARK trial, evaluating treatment suspension among patients with high-risk biochemically recurrent prostate cancer.

Neal Shore, MD, discusses...

01/26/2024

Oncology

Conference Coverage

CAR-T Cell Therapy vs Stem Cell Transplant for the Treatment of Patients With Multiple Myeloma

01/24/2024

Adriana Rossi , MD;

During a debate at the 2023 Lymphoma, Leukemia & Myeloma Congress, Adriana Rossi, MD, discussed whether CAR-T therapy is more beneficial than stem cell transplant in treatment regimens among patients with multiple myeloma.

During a debate at the 2023...

01/24/2024

Lymphoma, Leukemia & Myeloma Network

Thierry André, MD, Saint Antoine Hospital

Videos

Nivolumab Plus Ipilimumab Yields Superior PFS vs Chemotherapy for First-Line Treatment of Metastatic Colorectal Cancer

01/23/2024

Thierry André , MD;

Thierry Andre, MD, discusses the first results from the CheckMate 8HW study exploring nivolumab plus chemotherapy for the first-line treatment of microsatellite instability-high, mismatch repair-deficient metastatic colorectal cancer.

Thierry Andre, MD, discusses the...

01/23/2024

Oncology

Riccardo Lencioni, MD, University of Pisa School of Medicine

Videos

Addition of Durvalumab, Bevacizumab to TACE for Hepatocellular Carcinoma Improves PFS

01/23/2024

Riccardo Lencioni , MD;

Ricardo Lencioni, MD, shares results from the phase 3 EMERALD-1 study which found the addition of durvalumab and bevacizumab to TACE improved progression-free survival among patients with hepatocellular carcinoma, compared with TACE alone.

Ricardo Lencioni, MD, shares...

01/23/2024

Oncology

Dan Vogl, MD, University of Pennsylvania

Conference Coverage

Evaluating Bispecific T-Cell Engagers for the Treatment of Patients With Multiple Myeloma

01/23/2024

Dan Vogl , MD;

During the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, Dan Vogl, MD, discusses the optimal use of newly available bispecific T-cell engagers and other targets for multiple myeloma treatment.

During the 2023 Lymphoma,...

01/23/2024

Lymphoma, Leukemia & Myeloma Network

Faith E. Davies, MD, Perlmutter Cancer Center

Conference Coverage

Choosing a Treatment Strategy for Patients With Early Relapsed Multiple Myeloma

01/22/2024

Faith E. Davies , MD;

During the 2023 Lymphoma, Leukemia & Myeloma Congress, Faith E Davies, MD, discussed current treatment options for patients with early relapsed multiple myeloma.

During the 2023 Lymphoma,...

01/22/2024

Lymphoma, Leukemia & Myeloma Network

Carlyn Rose Tan, MD, Memorial Sloan Kettering Cancer Center

Conference Coverage

Prior Exposure to TCRT Associated With Lower CRS Incidence During Teclistamab Step-Up Dosing Phase Among Patients With R/R MM

01/22/2024

Carlyn Rose Tan , MD;

At the 65th ASH Annual Meeting, Carlyn Rose Tan, MD, presented data that for patients with R/R multiple myeloma, exposure to a T-cell redirection therapy correlated with a lower incidence of cytokine release syndrome during the teclistamab...

At the 65th ASH Annual Meeting,...

01/22/2024

Oncology

Anant Ramaswamy, MD, Tata Memorial Hospital

Videos

Addition of Docetaxel to FOLFOX/CAPOX Backbone Fails to Improve OS in Advanced GEJ/Gastric Cancer

01/20/2024

A. Ramaswamy ;

Anant Ramaswamy, MD, discusses results from the phase 3 DOC-GC study which explored the efficacy of docetaxel added to a FOLFOX/CAPOX backbone for patients with advanced GEJ and gastric cancers.

Anant Ramaswamy, MD, discusses...

01/20/2024

Oncology

Jeanne Tie, MBChB, MD, Peter MacCallum Cancer Centre

Videos

Circulating Tumor DNA-Guided vs Standard Management of Locally Advanced Rectal Cancer

01/20/2024

Jeanne Tie , MBChB, MD;

Professor Jeanne Tie, MBChB, FRACP, MD, discusses results from the AGITG DYNAMIC-Rectal study, which explored a ctDNA-guided approach to adjuvant chemotherapy following neoadjuvant chemoradiation for locally advanced rectal cancer.

Professor Jeanne Tie, MBChB,...

01/20/2024

Oncology

Ethan Ludmir, MD, MD Anderson Cancer Center

Videos

Adding Metastasis-Directed Therapy for Oligometastatic Pancreas Cancer

01/19/2024

Ethan Ludmir , MD;

Ethan Ludmir, MD, discusses results from the phase 2 EXTEND study, evaluating the addition of metastasis-directed therapy for oligometastatic pancreas cancer.

Ethan Ludmir, MD, discusses...

01/19/2024

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology